8-K Announcements
6Material company update
May 6, 2026·SEC
Material company update
Feb 23, 2026·SEC
Material company update
Feb 18, 2026·SEC
Tarsus Pharmaceuticals, Inc.(TARS)Earnings, Financials & Key Ratios
TARS•NASDAQ
$64.76
$2.76B mkt cap·Price updated May 6, 2026
AboutTarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.Show more
- Revenue$451M+146.7%
- EBITDA-$69M+42.1%
- Net Income-$66M+42.5%
- EPS (Diluted)-1.59+48.2%
- Gross Margin93.2%+0.2%
- EBITDA Margin-15.32%+76.5%
- Operating Margin-15.72%+76.1%
- Net Margin-14.72%+76.7%
- ROE-23.39%+57.3%
- ROIC-23.37%+73.6%
- Debt/Equity0.27-15.5%
- Interest Coverage-6.20+57.1%
TARS Key Insights
Tarsus Pharmaceuticals, Inc. (TARS) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Profits declining 19.9% over 5 years
- ✗Negative free cash flow
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Shares diluted 11.1% in last year
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
TARS Price & Volume
Tarsus Pharmaceuticals, Inc. (TARS) stock price & volume — 10-year historical chart
Loading chart...
TARS Growth Metrics
Tarsus Pharmaceuticals, Inc. (TARS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years159.54%
TTM128.99%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM54.01%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM58.24%
Return on Capital
10 Years-33.8%
5 Years-34.16%
3 Years-43.5%
Last Year-19.64%
TARS Recent Earnings
Tarsus Pharmaceuticals, Inc. (TARS) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 7/12 qtrs (58%)
Q1 2026Latest
Feb 23, 2026EPS
$0.20
Est $0.10
-94.2%
Revenue
$152M
Est $145M
+4.9%
Q4 2025
Nov 4, 2025EPS
$0.30
Est $0.35
+14.3%
Revenue
$119M
Est $145M
-17.9%
Q3 2025
Aug 6, 2025EPS
$0.48
Est $0.33
-45.5%
Revenue
$103M
Est $113M
-9.2%
Q2 2025
May 1, 2025EPS
$0.64
Est $0.69
+7.2%
Revenue
$78M
Est $99M
-21.0%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 23, 2026 | $0.20vs $0.10-94.2% | $152Mvs $145M+4.9% |
| Q4 2025 | Nov 4, 2025 | $0.30vs $0.35+14.3% | $119Mvs $145M-17.9% |
| Q3 2025 | Aug 6, 2025 | $0.48vs $0.33-45.5% | $103Mvs $113M-9.2% |
| Q2 2025 | May 1, 2025 | $0.64vs $0.69+7.2% | $78Mvs $99M-21.0% |
Based on last 12 quarters of dataView full earnings history →
TARS Peer Comparison
Tarsus Pharmaceuticals, Inc. (TARS) competitors in Ophthalmology Therapies and Delivery — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 LNTH | 5.61B | 86.15 | 25.26 | 0.5% | 15.15% | 20.58% | 0.00 | |
 NUVL | 6.92B | 104.26 | -26.53 | -45.12% | ||||
 PRAX | 7.61B | 337.95 | -25.07 | -100% | -58.74% | 0.00 | ||
 AEYE | 95.09M | 7.66 | -30.64 | 14.52% | -7.63% | -47.8% | 0.15 | |
 RXST | 279.79M | 6.78 | -7.14 | -3.89% | -36.58% | -17.01% | 0.04 | |
 AVXL | 309.52M | 3.34 | -6.19 | -31.55% | ||||
 INVA | 1.91B | 22.52 | 6.82 | 18.52% | 118.91% | 46.47% | 0.23 | |
 SGHT | 232.23M | 4.30 | -5.81 | -3.13% | -46.83% | -59.1% | 0.64 |
Compare TARS vs Peers
Tarsus Pharmaceuticals, Inc. (TARS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
TARS Income Statement
Tarsus Pharmaceuticals, Inc. (TARS) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 57.03M | 25.82M | 17.45M | 182.95M | 451.36M | 535.08M |
| Revenue Growth % | - | - | - | - | -54.73% | -32.42% | 948.62% | 146.71% | 128.99% |
| Cost of Goods Sold | 1K | 74K | 246K | 2.08M | 955K | 1.59M | 12.83M | 30.68M | 51.15M |
| COGS % of Revenue | - | - | - | 3.64% | 3.7% | 9.13% | 7.01% | 6.8% | - |
| Gross Profit | -1K▲ 0% | -74K▼ 7300.0% | -246K▼ 232.4% | 54.95M▲ 22438.2% | 24.86M▼ 54.8% | 15.85M▼ 36.2% | 170.13M▲ 973.1% | 420.68M▲ 147.3% | 483.93M▲ 0% |
| Gross Margin % | - | - | - | 96.36% | 96.3% | 90.87% | 92.99% | 93.2% | 90.44% |
| Gross Profit Growth % | - | -7300% | -232.43% | 22438.21% | -54.76% | -36.23% | 973.09% | 147.27% | - |
| Operating Expenses | 1.35M | 4.22M | 26.74M | 67.11M | 87.57M | 159.01M | 290.7M | 491.64M | 534.74M |
| OpEx % of Revenue | - | - | - | 117.68% | 339.22% | 911.4% | 158.89% | 108.93% | - |
| Selling, General & Admin | 448K | 1.06M | 7.93M | 25.4M | 44.95M | 108.7M | 237.31M | 427.32M | 478.76M |
| SG&A % of Revenue | - | - | - | 44.54% | 174.11% | 623.03% | 129.71% | 94.67% | - |
| Research & Development | 901K | 3.16M | 18.83M | 41.71M | 42.62M | 50.31M | 53.39M | 64.32M | 72.26M |
| R&D % of Revenue | - | - | - | 73.14% | 165.11% | 288.37% | 29.18% | 14.25% | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1000K |
| Operating Income | -1.35M▲ 0% | -4.3M▼ 218.4% | -26.98M▼ 527.8% | -12.16M▲ 54.9% | -62.71M▼ 415.9% | -143.16M▼ 128.3% | -120.57M▲ 15.8% | -70.97M▲ 41.1% | -50.81M▲ 0% |
| Operating Margin % | - | - | - | -21.32% | -242.92% | -820.53% | -65.9% | -15.72% | -9.5% |
| Operating Income Growth % | - | -218.37% | -527.8% | 54.95% | -415.85% | -128.28% | 15.78% | 41.14% | - |
| EBITDA | -1.35M | -4.22M | -26.74M | -11.85M | -62.39M | -142.28M | -119.34M | -69.15M | -49.45M |
| EBITDA Margin % | - | - | - | -20.77% | -241.66% | -815.5% | -65.23% | -15.32% | -9.24% |
| EBITDA Growth % | - | -213.12% | -532.98% | 55.7% | -426.69% | -128.07% | 16.12% | 42.06% | 54.1% |
| D&A (Non-Cash Add-back) | 1K | 74K | 246K | 312K | 326K | 877K | 1.23M | 1.82M | 1.36M |
| EBIT | -1.32M | -4.63M | -26.81M | -13.77M | -60.03M | -132.55M | -107.7M | -55.42M | -34.78M |
| Net Interest Income | 0 | 0 | 0 | 36K | 1.44M | 7.11M | 7.57M | 6.81M | 5.72M |
| Interest Income | 0 | 40K | 188K | 36K | 3.5M | 10.34M | 15.01M | 15.75M | 13.75M |
| Interest Expense | 0 | 40K | 188K | 0 | 2.06M | 3.23M | 7.45M | 8.94M | 2.18M |
| Other Income/Expense | 32K | -371K | 173K | -1.61M | 617K | 7.26M | 5.01M | 6.61M | 2.25M |
| Pretax Income | -1.32M▲ 0% | -4.67M▼ 254.2% | -26.81M▼ 474.2% | -13.77M▲ 48.6% | -62.09M▼ 350.9% | -135.89M▼ 118.8% | -115.55M▲ 15.0% | -64.36M▲ 44.3% | -48.56M▲ 0% |
| Pretax Margin % | - | - | - | -24.15% | -240.53% | -778.89% | -63.16% | -14.26% | -9.07% |
| Income Tax | 1K | 1K | 1K | 55K | -4K | 0 | 0 | 2.06M | -293K |
| Effective Tax Rate % | -0.08% | -0.02% | -0% | -0.4% | 0.01% | 0% | 0% | -3.2% | 0.6% |
| Net Income | -1.32M▲ 0% | -4.67M▼ 254.1% | -26.81M▼ 474.1% | -13.83M▲ 48.4% | -62.09M▼ 349.1% | -135.89M▼ 118.9% | -115.55M▲ 15.0% | -66.42M▲ 42.5% | -48.27M▲ 0% |
| Net Margin % | - | - | - | -24.25% | -240.51% | -778.89% | -63.16% | -14.72% | -9.02% |
| Net Income Growth % | - | -254.06% | -474.11% | 48.43% | -349.06% | -118.86% | 14.97% | 42.52% | 54.01% |
| Net Income (Continuing) | -1.32M | -4.67M | -26.81M | -13.83M | -62.09M | -135.89M | -115.55M | -66.42M | -48.27M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.31▲ 0% | -0.24▲ 22.6% | -1.32▼ 450.0% | -0.67▲ 49.2% | -2.52▼ 276.1% | -4.62▼ 83.3% | -3.07▲ 33.5% | -1.59▲ 48.2% | -1.12▲ 0% |
| EPS Growth % | - | 22.58% | -450% | 49.24% | -276.12% | -83.33% | 33.55% | 48.21% | 58.24% |
| EPS (Basic) | -0.31 | -0.24 | -1.32 | -0.67 | -2.52 | -4.62 | -3.07 | -1.59 | - |
| Diluted Shares Outstanding | 4.29M | 19.51M | 20.32M | 20.55M | 24.62M | 29.38M | 37.6M | 41.78M | 42.96M |
| Basic Shares Outstanding | 4.29M | 19.51M | 20.32M | 20.55M | 24.62M | 29.38M | 37.6M | 41.78M | 42.96M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
TARS Balance Sheet
Tarsus Pharmaceuticals, Inc. (TARS) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 2.38M | 58.03M | 170.66M | 175.95M | 225.38M | 256.13M | 356.7M | 522.78M | 537.23M |
| Cash & Short-Term Investments | 2.35M | 57.95M | 168.13M | 171.81M | 217.03M | 227.44M | 291.38M | 417.27M | 388.73M |
| Cash Only | 2.35M | 57.95M | 168.13M | 171.33M | 71.66M | 224.95M | 94.82M | 183.64M | 102.19M |
| Short-Term Investments | 0 | 0 | 0 | 483K | 145.37M | 2.5M | 196.56M | 233.63M | 286.54M |
| Accounts Receivable | 4K | 36K | 20K | 92K | 3.58M | 17.71M | 48.06M | 87.11M | 117.21M |
| Days Sales Outstanding | - | - | - | 0.59 | 50.64 | 370.59 | 95.88 | 70.44 | 57.79 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 3.11M | 2.62M | 4.37M | 4.57M |
| Days Inventory Outstanding | - | - | - | - | - | 711.9 | 74.56 | 52.01 | 29.71 |
| Other Current Assets | 20K | 20K | 20K | 0 | 0 | 0 | 0 | 560K | 26.72M |
| Total Non-Current Assets | 6K | 286K | 1.32M | 2.96M | 2.49M | 9.36M | 20.29M | 39.38M | 43.91M |
| Property, Plant & Equipment | 6K | 280K | 1.24M | 1.83M | 1.53M | 3.35M | 2.87M | 21.75M | 27.67M |
| Fixed Asset Turnover | - | - | - | 31.18x | 16.85x | 5.21x | 63.84x | 20.76x | 31.11x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 3.87M | 8.33M | 7.37M | 7.13M |
| Long-Term Investments | 0 | 0 | 0 | 0 | 371K | 631K | 3M | 3.87M | 16.3M |
| Other Non-Current Assets | 0 | 6K | 81K | 1.13M | 585K | 1.51M | 6.09M | 6.39M | 21.66M |
| Total Assets | 2.39M▲ 0% | 58.32M▲ 2341.0% | 171.97M▲ 194.9% | 178.91M▲ 4.0% | 227.86M▲ 27.4% | 265.49M▲ 16.5% | 376.99M▲ 42.0% | 562.16M▲ 49.1% | 581.13M▲ 0% |
| Asset Turnover | - | - | - | 0.32x | 0.11x | 0.07x | 0.49x | 0.80x | 0.99x |
| Asset Growth % | - | 2341.02% | 194.9% | 4.03% | 27.36% | 16.51% | 42% | 49.12% | 138.58% |
| Total Current Liabilities | 179K | 819K | 5.39M | 11.48M | 15.43M | 36.94M | 80.61M | 135.69M | 143.51M |
| Accounts Payable | 175K | 456K | 2.24M | 2.86M | 5.5M | 17.77M | 27.74M | 16.39M | 24.13M |
| Days Payables Outstanding | 63.88K | 2.25K | 3.32K | 502.38 | 2.1K | 4.07K | 789.39 | 194.93 | 194.86 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 1K | 0 | 304K | 56K | 0 | 0 | 0 | 117.5M | 143.51M |
| Current Ratio | 13.31x | 70.85x | 31.68x | 15.33x | 14.61x | 6.93x | 4.42x | 3.85x | 3.85x |
| Quick Ratio | 13.31x | 70.85x | 31.68x | 15.33x | 14.61x | 6.85x | 4.39x | 3.82x | 3.82x |
| Cash Conversion Cycle | - | - | - | - | - | -2.99K | -618.95 | -72.48 | -107.36 |
| Total Non-Current Liabilities | 3.56M | 63.5M | 605K | 699K | 19.53M | 31.57M | 71.84M | 83.04M | 88.68M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 19.43M | 29.82M | 71.84M | 83.04M | 0 |
| Capital Lease Obligations | 0 | 100K | 549K | 585K | 52K | 0 | 0 | 10.6M | 20.75M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 3.56M | 63.4M | 56K | 114K | 48K | 1.75M | 0 | -10.6M | 78.08M |
| Total Liabilities | 3.74M | 64.32M | 5.99M | 12.18M | 34.96M | 68.5M | 152.46M | 218.73M | 232.18M |
| Total Debt | 0 | 164K | 831K | 1.89M | 20.21M | 30.22M | 72.45M | 93.64M | 0 |
| Net Debt | -2.35M | -57.79M | -167.3M | -169.44M | -51.45M | -194.73M | -22.37M | -90M | -102.19M |
| Debt / Equity | - | - | 0.01x | 0.01x | 0.10x | 0.15x | 0.32x | 0.27x | 0.27x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | -0.00x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | 2.07x |
| Interest Coverage | - | -115.73x | -142.61x | - | -29.08x | -41.10x | -14.46x | -6.20x | -15.96x |
| Total Equity | -1.35M▲ 0% | -6M▼ 343.5% | 165.98M▲ 2864.0% | 166.73M▲ 0.5% | 192.9M▲ 15.7% | 196.99M▲ 2.1% | 224.53M▲ 14.0% | 343.43M▲ 53.0% | 348.95M▲ 0% |
| Equity Growth % | - | -343.5% | 2864.03% | 0.45% | 15.7% | 2.12% | 13.98% | 52.95% | 127.8% |
| Book Value per Share | -0.32 | -0.31 | 8.17 | 8.11 | 7.84 | 6.70 | 5.97 | 8.22 | 8.12 |
| Total Shareholders' Equity | -1.35M | -6M | 165.98M | 166.73M | 192.9M | 196.99M | 224.53M | 343.43M | 348.95M |
| Common Stock | 1K | 2K | 4K | 4K | 5K | 5K | 6K | 6K | 6K |
| Retained Earnings | -1.36M | -6.03M | -32.84M | -46.67M | -108.76M | -244.66M | -360.21M | -426.63M | -433.6M |
| Treasury Stock | -9K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -1K | 0 | 0 | 0 | -74K | -2K | 179K | 381K | -298K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
TARS Cash Flow Statement
Tarsus Pharmaceuticals, Inc. (TARS) cash flow — operating, investing & free cash flow history
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -1.18M | -3.67M | -21.14M | 3.75M | -49.03M | -117.49M | -83.03M | -12.45M | -12.45M |
| Operating CF Margin % | - | - | - | 6.57% | -189.92% | -673.43% | -45.38% | -2.76% | - |
| Operating CF Growth % | - | -210.48% | -475.5% | 117.73% | -1408.16% | -139.63% | 29.33% | 85% | 374.76% |
| Net Income | -1.32M | -4.67M | -26.81M | -13.83M | -62.09M | -135.89M | -115.55M | -66.42M | -48.27M |
| Depreciation & Amortization | 1K | 37K | 96K | 312K | 325K | 877K | 1.23M | 1.82M | 1.73M |
| Stock-Based Compensation | 9K | 18K | 839K | 8.46M | 13.46M | 19.83M | 27.82M | 41.72M | 46.76M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -116K | 457K | 3.28M | 7.44M | 227K | -2.61M | -360K | -4.21M | -33.23M |
| Working Capital Changes | 126K | 485K | 1.46M | 1.37M | -951K | 306K | 3.84M | 14.64M | 16.55M |
| Change in Receivables | -4K | -32K | 16K | -73K | -3.49M | -14.13M | -30.14M | -39.05M | -53.24M |
| Change in Inventory | 0 | 0 | 0 | 0 | 3.49M | -3.11M | -2.05M | -1.75M | -1.86M |
| Change in Payables | 131K | 245K | 3.24M | 3.88M | 821K | 13.24M | 40.34M | 6.91M | 3.31M |
| Cash from Investing | -7K | -175K | -456K | -586K | -144.63M | 140.6M | -199.19M | -42.12M | -65.73M |
| Capital Expenditures | -7K | -175K | -456K | -586K | -506K | -1.5M | -1.57M | -9.86M | -15.09M |
| CapEx % of Revenue | - | - | - | 1.03% | 1.96% | 8.61% | 0.86% | 2.18% | - |
| Acquisitions | 0 | 0 | 0 | 0 | 144.12M | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | -144.12M | -4M | -5M | 0 | 0 |
| Cash from Financing | 3.56M | 59.45M | 131.77M | 21K | 93.99M | 130.18M | 154.66M | 143.39M | 8.03M |
| Debt Issued (Net) | 0 | 1.99M | 0 | 0 | 19.13M | 10M | 39.6M | 0 | 0 |
| Equity Issued (Net) | 3.56M | 57.46M | 131.4M | 21K | 74.86M | 120.18M | 115.06M | 143.39M | 6.83M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | -28K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 0 | 370K | 0 | 0 | 0 | 0 | 0 | 1.2M |
| Net Change in Cash | 2.37M▲ 0% | 55.6M▲ 2241.9% | 110.18M▲ 98.2% | 3.18M▼ 97.1% | -99.67M▼ 3231.4% | 153.29M▲ 253.8% | -127.57M▼ 183.2% | 88.82M▲ 169.6% | -74.16M▲ 0% |
| Free Cash Flow | -1.19M▲ 0% | -3.85M▼ 223.4% | -21.59M▼ 461.2% | 3.16M▲ 114.6% | -49.54M▼ 1666.6% | -123M▼ 148.3% | -84.59M▲ 31.2% | -22.31M▲ 73.6% | -31.54M▲ 0% |
| FCF Margin % | - | - | - | 5.54% | -191.88% | -704.96% | -46.24% | -4.94% | -5.89% |
| FCF Growth % | - | -223.36% | -461.17% | 114.64% | -1666.6% | -148.29% | 31.22% | 73.63% | 56.72% |
| FCF per Share | -0.28 | -0.20 | -1.06 | 0.15 | -2.01 | -4.19 | -2.25 | -0.53 | -0.53 |
| FCF Conversion (FCF/Net Income) | 0.90x | 0.79x | 0.79x | -0.27x | 0.79x | 0.86x | 0.72x | 0.19x | 0.65x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 2.88M | 0 | 0 | 2.12M |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
TARS Key Ratios
Tarsus Pharmaceuticals, Inc. (TARS) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | -33.52% | -8.31% | -34.53% | -69.71% | -54.83% | -23.39% | -14.19% |
| Return on Invested Capital (ROIC) | - | - | - | -67.8% | -149.43% | -88.47% | -23.37% | -23.37% |
| Gross Margin | - | - | 96.36% | 96.3% | 90.87% | 92.99% | 93.2% | 90.44% |
| Net Margin | - | - | -24.25% | -240.51% | -778.89% | -63.16% | -14.72% | -9.02% |
| Debt / Equity | - | 0.01x | 0.01x | 0.10x | 0.15x | 0.32x | 0.27x | 0.27x |
| Interest Coverage | -115.73x | -142.61x | - | -29.08x | -41.10x | -14.46x | -6.20x | -15.96x |
| FCF Conversion | 0.79x | 0.79x | -0.27x | 0.79x | 0.86x | 0.72x | 0.19x | 0.65x |
| Revenue Growth | - | - | - | -54.73% | -32.42% | 948.62% | 146.71% | 128.99% |
TARS SEC Filings & Documents
Tarsus Pharmaceuticals, Inc. (TARS) SEC filings — annual & quarterly reports (10-K, 10-Q)
TARS Frequently Asked Questions
Tarsus Pharmaceuticals, Inc. (TARS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Tarsus Pharmaceuticals, Inc. (TARS) reported $535.1M in revenue for fiscal year 2025.
Tarsus Pharmaceuticals, Inc. (TARS) grew revenue by 146.7% over the past year. This is strong growth.
Tarsus Pharmaceuticals, Inc. (TARS) reported a net loss of $48.3M for fiscal year 2025.
Dividend & Returns
Tarsus Pharmaceuticals, Inc. (TARS) has a return on equity (ROE) of -23.4%. Negative ROE indicates the company is unprofitable.
Tarsus Pharmaceuticals, Inc. (TARS) had negative free cash flow of $31.5M in fiscal year 2025, likely due to heavy capital investments.
Explore More TARS
Tarsus Pharmaceuticals, Inc. (TARS) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates